Itonis Inc (ITNS) 0.0070 $ITNS Itonis, Inc. Signs

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Itonis Inc (ITNS) 0.0070 $ITNS

Itonis, Inc. Signs Fantasy Grudge, LLC for Its Licensed MyECheck Point of Sale Mobile Payment Application
ACCESSWIRE - Fri May 08, 8:00AM CDT
LAGUNA HILLS, CA / ACCESSWIRE / May 8, 2015 / Itonis, Inc. (PINKSHEETS: ITNS) Itonis is pleased to announce that it has signed Fantasy Grudge, LLC to an agreement for retail use of MyECheck, Inc.'s patented mobile payment application. Itonis holds a license from MyECheck (OTC: MYEC) for the patented mobile payment application. The agreement allows Fantasy Grudge's customers to use MyECheck's mobile payment application when making website purchase transactions.

Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part V
Anthony Cataldo - at Seeking Alpha - Sat Apr 18, 6:09AM CDT

INSY: 59.00 (+0.17)

Hensley Brothers Distribution, LLC Reveals Cruise Line Distribution Channel For Itonis Holdings? Emesyl Nausea Relief
ACCESSWIRE - Tue Mar 24, 7:58AM CDT
LOS ANGELES, CA / ACCESSWIRE / March 24, 2015 / Hensley Brothers Distribution, LLC., a California based consumer products distribution company distributing a diverse class of consumer products domestically and internationally revealed their cruise line distribution channel for EMESYL Nausea Relief.

Hensley Brothers Distribution Announces Nationwide Rollout For Itonis Holdings' Emesyl Nausea Relief
ACCESSWIRE - Wed Mar 18, 12:22PM CDT
LOS ANGELES, CA / ACCESSWIRE / March 18, 2015 / Hensley Brothers Distribution, LLC, a California based consumer products distribution company distributing a diverse class of consumer products domestically and internationally announced today that they are rolling out EMESYL Nausea Relief nationwide.

53 Marijuana Stocks - A Post-Mortem: Part III And Epilogue
Anthony Cataldo - at Seeking Alpha - Thu Mar 05, 2:25PM CST

VPCO: 0.55 (-0.05)

12 More Marijuana Stocks To Avoid - Part I
Anthony Cataldo - at Seeking Alpha - Thu Feb 19, 6:21AM CST

XXII: 1.07 (+0.01), VPCO: 0.55 (-0.05)

Itonis to Ship More Emesyl(TM) Nausea Relief to Hensley Brothers Distribution, LLC
ACCESSWIRE - Tue Feb 03, 9:30AM CST
LAGUNA HILLS, CA / ACCESSWIRE / February 03, 2015 / Itonis, Inc. (OTC PINKSHEETS: ITNS)

Itonis Delivers First Shipment of its Emesyl(TM) Nausea Relief Product to Hensley Brothers Distribution, Commencing Domestic Retail
ACCESSWIRE - Tue Jan 27, 8:01AM CST
Itonis Delivers First Shipment of its Emesyl(TM) Nausea Relief Product to Hensley Brothers Distribution, Commencing Domestic Retail Sales Distribution

Itonis Pharmaceuticals Announces Completion of Stability Test for Emesyl(R) and Delivery Date of Emesyl(R) with New Packaging Design
ACCESSWIRE - Thu Dec 18, 9:41AM CST
LAGUNA HILLS, CA / ACCESSWIRE / December 18, 2014 / Itonis, Inc. (OTC PINKSHEETS: ITNS) is pleased to announce that it has received confirmation from its manufacturer, Oasis Health Products, that its Emesyl(R) nausea relief product has passed its Stability Test to enable the company to market Emesyl(R) with a 2-year expiration date.

Itonis Pharmaceuticals Announces Emesyl(R) Website on New Nausea Relief Product
ACCESSWIRE - Tue Oct 21, 8:04AM CDT
Image: https://www.baystreet.ca/uploads/Itonis%20Logo.jpg

Itonis Pharmaceuticals Announces First Emesyl(R) Manufacturer Production Release Date
Marketwire - Tue Aug 12, 7:31AM CDT
Itonis, Inc. (PINKSHEETS: ITNS)

Itonis Pharmaceuticals Authorizes Start of Emesyl(R) Inaugural Production Run
Marketwire - Wed Jun 25, 7:03AM CDT
Itonis, Inc. (PINKSHEETS: ITNS) Itonis is pleased to announce that, with the finalization of its new packaging design and product labeling, it has given the go ahead to Oasis Health Products to produce 16,000 units of its Emesyl(R) homeopathic product. Itonis has pre-paid necessary funds to Oasis to commence the inaugural production run.

Itonis Pharmaceuticals Completes Final Package Design, Enabling Start of Emesyl(R) Production
Marketwire - Thu Jun 19, 9:00AM CDT
Itonis, Inc. (PINKSHEETS: ITNS) is pleased to announce that the final product packaging and bottle label designs for its Emesyl(R) over-the-counter homeopathic product for nausea relief are now complete. The finalized packaging design includes the 800 product phone number, the product information website, the product UPC code, and a brand new visual look that is very appealing to consumers. New pictures of the final box and bottle designs can be found on the company's website news tab at # http://www.itonisholdings.com/news.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 61

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 144

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Air Sealing First: Boosting Home Comfort & Efficiency

Updated Category News Views 69

Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 181

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 28

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 80

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 149

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 252

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 96

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 331

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Warner Bros. Discovery's Remarkable Stock Surge Explained

Updated Category News Views 309

Warner Bros. Discovery Experiences Impressive Stock Surge Warner Bros. Discovery Inc. (NASDAQ: WBD) has been making headlines recently, with its stock surging dramatically. Investors and market enthusiasts are keenly observing this upward trend, particularly following a substantial rally. Record-Breaking Rally The company achieved an incredible milestone with its largest...

Continue Reading
Stellantis Reports 20% Q3 Shipment Drop, Market Reactions

Updated Category News Views 98

Stellantis Faces Significant Q3 Shipment Decline Stellantis (EPA: STLAM) (NYSE: STLA) recently reported a 20% drop in global shipments for the third quarter, prompting a notable reaction in the markets. The decline has been attributed to several factors including strategic inventory reduction measures and delays in the release of new models. During this challenging...

Continue Reading
Stifel Affirms Buy Rating on Elanco Amid New Drug Approval

Updated Category News Views 70

Stifel Stands Firm on Elanco Animal Health Stifel, a prominent financial services firm, has recently reaffirmed its Buy rating for Elanco Animal Health (NYSE: ELAN) and has kept its price target at $20.00 per share. This decision comes on the heels of the U.S. Food and Drug Administration's (FDA) approval of Elanco's new drug, Zenrelia, which serves as a significant boost...

Continue Reading
ChargePoint and Siemens Drive EV Infrastructure Innovation

Updated Category News Views 94

ChargePoint and Siemens Lead the Charge in Clean Tech The clean tech revolution is moving at an impressive pace, particularly with the growth of electric vertical takeoff and landing (eVTOL) aircraft and electric vehicle (EV) infrastructure. Companies like ChargePoint Holdings Inc (NYSE: CHPT) and Siemens AG (OTCPK: SIEGY) are crucial in shaping a sustainable future for...

Continue Reading
Elevance Health Faces Class Action: Investors Seek Remedies

Updated Category News Views 259

Opportunities for Investors in Elevance Health Class Action The recent developments surrounding Elevance Health, Inc. have prompted considerable attention, particularly among investors who have experienced substantial financial losses. The law firm Robbins Geller Rudman & Dowd LLP has initiated a class action lawsuit targeting Elevance Health, which operates in the health...

Continue Reading